دورية أكاديمية
أعرض في EDS

Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.

التفاصيل البيبلوغرافية
العنوان: Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
المؤلفون: Singh P; Cogent Biosciences, Waltham, MA., Belliveau P; Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Manchester, NH; and., Towle J; Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Manchester, NH; and., Neculau AE; Faculty of Medicine, Transilvania University of Brasov, Brasov, Romania., Dima L; Faculty of Medicine, Transilvania University of Brasov, Brasov, Romania.
المصدر: American journal of therapeutics [Am J Ther] 2024 May-Jun 01; Vol. 31 (3), pp. e258-e267.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9441347 Publication Model: Print Cited Medium: Internet ISSN: 1536-3686 (Electronic) Linking ISSN: 10752765 NLM ISO Abbreviation: Am J Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: 1998- : Philadelphia, PA : Lippincott Williams & Wilkins
Original Publication: New York, NY : Chapman & Hall, c1994-
مواضيع طبية MeSH: Edaravone*/administration & dosage , Edaravone*/pharmacology , Edaravone*/therapeutic use , Amyotrophic Lateral Sclerosis*/drug therapy , Neuroprotective Agents*/administration & dosage , Neuroprotective Agents*/therapeutic use , Neuroprotective Agents*/adverse effects, Humans ; Administration, Oral ; Suspensions ; Biological Availability
مستخلص: Background: Amyotrophic lateral sclerosis (ALS) is characterized by loss of motor neurons due to degeneration of nerve cells within the brain and spinal cord. Early symptoms include limb weakness, twitching or muscle cramping, and slurred speech. As the disease progresses, difficulty breathing, swallowing, and paralysis can lead to death. Currently, there are no medications that cure ALS, and guidelines recommend treatments focused on symptom management. Intravenous (IV) edaravone was approved by the US Food and Drug Administration (FDA) in 2017 as a treatment to slow the progression of ALS. In May 2022, the FDA approved an oral suspension (ORS) formulation of edaravone.
Mechanism of Action: The mechanism of action of edaravone is not well defined. However, its neuroprotective effects are thought to result from antioxidant properties occurring through elimination of free radicals.
Pharmacokinetics: Edaravone ORS (105 mg) has a bioavailability of 57% when compared with edaravone IV (60 mg). The ORS should be taken on an empty stomach in the morning, with water and no food or beverages, for 1 hour. Edaravone is bound to albumin (92%), has a mean volume of distribution of 63.1 L, a half-life of 4.5-9 hours, and a total clearance of 35.9 L/h after intravenous administration. Edaravone is metabolized into nonactive sulfate and glucuronide conjugates.
Clinical Trials: The FDA approval was based on studies of the pharmacokinetics, safety, tolerability, and bioavailability of edaravone ORS. A phase III, global, multicenter, open-label safety study was conducted on edaravone ORS in 185 patients with ALS over 48 weeks. The most reported treatment-emergent adverse events were falls, muscular weakness, and constipation. Serious treatment-emergent adverse events included disease worsening, dysphagia, dyspnea, and respiratory failure.
Therapeutic Advance: Oral edaravone is an ALS treatment that can be self-administered or administered by a caregiver, precluding the need for administration by a health care professional in an institutional setting.
Competing Interests: The authors have no conflicts of interest to declare.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098.
Siddique N, Siddique T. Amyotrophic Lateral Sclerosis Overview. In: GeneReviews. Seattle, WA: University of Washington, Seattle; 1993:1–50. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1450/?report=reader#_NBK1450_pubdet_. Accessed January 17, 2023.
Mehta P, Raymond J, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph Lateral Scler Frontotemporal Degen. 2023;24:108–116.
Rizzuti M, Sali L, Melzi V, et al. Genomic and transcriptomic advances in amyotrophic lateral sclerosis. Ageing Res Rev. 2023;92:102126.
Soares P, Silva C, Chavarria D, et al. Drug discovery and amyotrophic lateral sclerosis: emerging challenges and therapeutic opportunities. Ageing Res Rev. 2023;83:101790.
Lacorte E, Ferrigno L, Leoncini E, et al. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: a systematic review. Neurosci Biobehav Rev. 2016;66:61–79.
Chiò A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986.
Brotman RG, Moreno-Escobar MC, Joseph J, et al. Amyotrophic lateral sclerosis. In: StatPearls [Internet]. Treasure Island, FL. StatPearls Publishing; 2023.
Mead RJ, Shan N, Reiser HJ, et al. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov. 2023;22:185–212.
Moore DH, Miller RG, the Western ALS Study Group. Improving efficiency of ALS clinical trials. (12th international Symposiumon ALS/MND). Amyotroph Lateral Scler Mot Neuron Disord. 2001;2:20.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227–1233.
EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19:360–375.
Kawashima Y, Yamada M, Furuie H, et al. Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: a systematic review. Neuropsychopharmacol Rep. 2023;43:320–327.
RILUTEK® (Riluzole) Tablets. Food Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020599s011s012lbl.pdf. Accessed January 17, 2023.
Tiglutik® (riluzole). Food Drug Administration. Available at: https://tiglutik.com/wp-content/uploads/2020/07/TIGLUTIK_5PagePacket_ORAL.pdf. Accessed July 25, 2023.
Exservan® (riluzole). Food Drug Administration. Label (exservanhcp.com). Accessed July 25, 2023.
Relyvrio (Sodium Phenylbutyrate Taurursodiol). Food Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf. 2022. Accessed January 17, 2023.
Cerillo JL, Parmar M. Tofersen. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023.
Radicava® (EDARAVONE). Food Drug Administration. Published May 2022. Available at: https://www.radicava.com/pdfs/radicava-prescribing-information.pdf. Accessed January 18, 2023.
Neupane P, Thada PK, Singh P, et al. Investigating edaravone use for management of amyotrophic lateral sclerosis (ALS): a narrative review. Cureus. 2023;15:e33746.
Pattee GL, Genge A, Couratier P, et al. Oral edaravone - introducing a flexible treatment option for amyotrophic lateral sclerosis. Expert Rev Neurother. 2023;23:859–866.
Watanabe K, Tanaka M, Yuki S, et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018;62:20–38.
Takei K, Watanabe K, Yuki S, et al. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degen. 2017;18:5–10.
Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19:185–193.
Jami MS, Salehi-Najafabadi Z, Ahmadinejad F, et al. Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochem Int. 2015;90:134–141.
Homma T, Kobayashi S, Sato H, et al. Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro. Exp Cell Res. 2019;384:111592.
Cho H, Shukla S. Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals (Basel). 2020;14:29. Nelson S. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis. Expert Rev Neurother. 2023;23(10):859-866. doi: 10.1080/14737175.2023.2251687.
Saha S, Buttari B, Panieri E, et al. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020;25:5474.
Michaličková D, Kübra Öztürk H, Hroudová J, et al. Edaravone attenuates disease severity of experimental auto-immune encephalomyelitis and increases gene expression of Nrf2 and HO-1. Physiol Res. 2022;71:147–157.
Halliwell B. Understanding mechanisms of antioxidant action in health and disease. Nat Rev Mol Cell Biol. 2024;25:13–33.
Watanabe T, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:211.
Berry J, Brooks B, Genge A, et al. Radicava/edaravone findings in biomarkers from amyotrophic lateral sclerosis (REFINE-ALS): protocol and study design. Neurol Clin Pract. 2021;11:e472–e479.
Shimizu H, Nishimura Y, Shiide Y, et al. Evaluation of pharmacokinetics, safety, and Drug‐drug interactions of an oral suspension of Edaravone in healthy adults. Clin Pharmacol Drug Dev. 2021;10:1174–1187.
Nakamaru Y, Kakubari M, Yoshida K, et al. An open-label, single-dose study to evaluate the pharmacokinetic variables of edaravone in subjects with mild, moderate, or no renal impairment. Clin Ther. 2020;42:1699–1714.
Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79:121–130.
Genge A, Pattee GL, Sobue G, et al. Oral Edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle Nerve. 2023;67:124–129.
Yoshino H, Kimura A. Investigation of the therapeutic effects of Edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler. 2006;7:247–251.
Radicava. BOOK Online RED. IBM micromedex [database online]. Truven health analytics/IBM watson health; 2020. Available at: https://www.micromedexsolutions. com. Accessed November17, 2023.
Tanabe M. Mitsubishi Tanabe Pharma america Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS. Mitsubishi Tanabe Pharma America. Published December 22, 2020. Available at: https://www.mt-pharma-america.com/2020/12/22/mitsubishi-tanabe-pharma-america-announces-initiation-ofopen-label-extension-study-of-oral-edaravone-in-als/. Accessed February 23, 2022.
Writing Group. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of Edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–512.
Jayasinghe M, Jena R, Singhal M, et al. Ethnical disparities in response to edaravone in patients with amyotrophic lateral sclerosis. Cureus. 2022;14:e25960.
المشرفين على المادة: S798V6YJRP (Edaravone)
0 (Neuroprotective Agents)
0 (Suspensions)
تواريخ الأحداث: Date Created: 20240501 Date Completed: 20240501 Latest Revision: 20240529
رمز التحديث: 20240529
DOI: 10.1097/MJT.0000000000001742
PMID: 38691665
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-3686
DOI:10.1097/MJT.0000000000001742